BeStock  
Stocks › Biotechnology › VRDN

Viridian Therapeutics VRDN

US equityMarket cap rank #2344Biotechnology
$29.96 −$1.48 (-4.71%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $29.96 0.00%
Open$31.12
Prev close$31.44
Day range$29.87 – $31.75
Volume1.75M
Market cap$3.40B
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership117.3%-0.14 pts vs. prior quarter
Institutions holding278+5 vs. prior quarter
Insider trades (recent)38 buys / 11 sellsNet buying
Short interest15.04% of floatDays to cover 9.1 · as of 30 Oct 2026
Short-sale volume share19.2%5-day average of daily volume

Short-sale volume as % of daily volume

9%16%23%30%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$19.42M (9 inflow days, 11 outflow days).

Net flow by order size, last 20 sessions

−$18.5MSuper−$966.1KBig−$3.0MMid+$366.6KSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 40.5% of shares outstanding.

Largest holders

  • FMR15.42%
  • BlackRock8.22%
  • Bellevue Asset Management AG5.93%
  • Paradigm Biocapital Advisors LP5.92%
  • T. Rowe Price Group, Inc.5.06%
  • Point72 Asset Management, L.P.5.01%
  • Fairmount Funds Management LLC4.48%
  • State Street Global Advisors4.29%

By investor type

  • Mutual Fund69.20%
  • Hedge Fund32.95%
  • VC/PE Fund8.75%
  • Public Company2.97%
  • Private Company1.46%
  • Sovereign Wealth Fund1.32%
  • Government Pension Fund0.30%
  • Insurance Company0.28%

Reported short interest has fallen from 16.79% to 15.04% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
FMR Mutual Fund 2026/Q3 +904,397 15.4%
BlackRock Mutual Fund 2026/Q3 +777,662 8.2%
Davern Capital Partners, LP Hedge Fund 2026/Q3 +560,710 0.5%
Geode Capital Management, LLC Mutual Fund 2026/Q3 +301,900 2.5%
Point72 Asset Management, L.P. Hedge Fund 2026/Q3 +3,344,299 5.0%
Paradigm Biocapital Advisors LP Hedge Fund 2026/Q3 +3,574,895 5.9%
T. Rowe Price Group, Inc. Mutual Fund 2026/Q3 +2,542,391 5.1%
Deep Track Capital, LP VC/PE Fund 2026/Q3 +2,198,796 3.2%
Caligan Partners, LP Hedge Fund 2026/Q3 +2,193,981 1.9%
State Street Global Advisors Mutual Fund 2026/Q3 +1,452,091 5.4%
UBS Asset Management Mutual Fund 2026/Q3 +1,233,326 2.1%
FMR Mutual Fund 2026/Q3 +1,225,363 14.7%
Fairmount Funds Management LLC Hedge Fund 2026/Q3 +1,176,470 4.5%
Vanguard Portfolio Management, LLC Mutual Fund 2026/Q3 +1,111,350 2.4%
Arrowstreet Capital, Limited Partnership Mutual Fund 2026/Q3 +1,089,134 1.0%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
18 Aug 2026 Jennifer Tousignant Chief Legal Officer Open Market Disposition -4,212 $24.50 –
18 Aug 2026 Jennifer Tousignant Chief Legal Officer Derivative Exercise and Sale -10,000 $24.50 –
13 Aug 2026 Radhika Tripuraneni Chief Medical Officer Derivative Exercise and Retained +40,000 $13.21 40,000
30 Jun 2026 Arlene Morris Independent Director Other Derivative Acquisition +32,341 $18.48 32,341
30 Jun 2026 Jeffrey Ajer Independent Director Other Derivative Acquisition +32,341 $18.48 32,341
30 Jun 2026 Tomas Kiselak Independent Chairperson of Board Other Derivative Acquisition +32,341 $18.48 32,341
30 Jun 2026 Christopher Cain Independent Director Other Derivative Acquisition +32,341 $18.48 32,341
30 Jun 2026 Jennifer Moses Independent Director Other Derivative Acquisition +32,341 $18.48 32,341
30 Jun 2026 Sarah Gheuens Independent Director Other Derivative Acquisition +32,341 $18.48 32,341
10 May 2026 Fairmount Funds Management LLC Open Market Acquisition +1,176,470 $17.00 5,090,928
3 Mar 2026 Thomas Beetham Chief Operating Officer Intent to Sell (Form 144) -3,048 $30.19 –
3 Mar 2026 Stephen Mahoney Chief Executive Officer Intent to Sell (Form 144) -7,408 $30.19 –
3 Mar 2026 Seth Harmon Chief Financial Officer Intent to Sell (Form 144) -2,031 $30.19 –
3 Mar 2026 Jennifer Tousignant Chief Legal Officer Intent to Sell (Form 144) -1,675 $30.19 –
2 Mar 2026 Thomas Beetham Chief Operating Officer Sale to Issuer -3,048 $30.19 13,361
2 Mar 2026 Thomas Beetham Chief Operating Officer Derivative Exercise and Retained +9,409 – 13,361
2 Mar 2026 Stephen Mahoney Chief Executive Officer Sale to Issuer -7,408 $30.19 33,349
2 Mar 2026 Stephen Mahoney Chief Executive Officer Derivative Exercise and Retained +18,357 – 33,349
2 Mar 2026 Seth Harmon Chief Financial Officer Sale to Issuer -2,031 $30.19 7,850
2 Mar 2026 Seth Harmon Chief Financial Officer Derivative Exercise and Retained +6,267 – 7,850

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 17,042,236 15.0% 9.1
15 Oct 2026 18,002,311 15.9% 8.0
30 Sep 2026 17,965,668 15.9% 8.9
15 Sep 2026 19,465,251 17.2% 15.7
31 Aug 2026 19,511,841 17.2% 16.6
14 Aug 2026 19,026,492 16.8% 9.1

Discussion

No comments yet — be the first to weigh in on VRDN.

Sign in to join the discussion.

Scroll to Top